Clinical Trial Update: Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC [Phase 3]

View source ↗

Summary

Phase III trial update for SY-5007, a RET inhibitor, in locally advanced or metastatic RET fusion-positive non-small cell lung cancer; study currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SY-5007 (SY-5007)

Snippet

Sponsor: Shouyao Holdings (Beijing) Co. LTD | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING